Evaluation of N-acetyl-S-(p-chlorophenylcarbamoyl)cysteine as an irreversible inhibitor of mammalian thioredoxin reductase1

References

• Xiao GQ, Liang BX, Chen SH, et al. 3-Nitro-2H-chromenes as a new class of inhibitors against thioredoxin reductase and proliferation of cancer cells. Arch Pharm (Weinheim) 2012;345:767–70
   PubMed Web of Science ®Google Scholar
• Liu Y, Li Y, Yu S, Zhao G. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents. Curr Drug Targets 2012;13:1432–44
   PubMed Web of Science ®Google Scholar
• Navakoski de Oliveira K, Andermark V, von Grafenstein S, et al. Butyltin(IV) benzoates: inhibition of thioredoxin reductase, tumor cell growth inhibition, and interactions with proteins. ChemMedChem 2013;8:256–64
   PubMed Web of Science ®Google Scholar
• Xu J, Arner ES. Pyrroloquinoline quinone modulates the kinetic parameters of the mammalian selenoprotein thioredoxin reductase 1 and is an inhibitor of glutathione reductase. Biochem Pharmacol 2012;83:815–20
   PubMed Web of Science ®Google Scholar
• Wang L, Yang Z, Fu J, et al. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent. Free Radic Biol Med 2012;52:898–908
   PubMed Web of Science ®Google Scholar
• Arner ES. Focus on mammalian thioredoxin reductases – important selenoproteins with versatile functions. Biochim Biophys Acta 2009;1790:495–526
   PubMed Web of Science ®Google Scholar
• Cai W, Zhang B, Duan D, et al. Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells. Toxicol Appl Pharmacol 2012;262:341–8
   PubMed Web of Science ®Google Scholar
• Yoon BI, Kim DY, Jang JJ, Han JH. Altered expression of thioredoxin reductase-1 in dysplastic bile ducts and cholangiocarcinoma in a hamster model. J Vet Sci 2006;7:211–16
   PubMed Web of Science ®Google Scholar
• Berggren M, Gallegos A, Gasdaska JR, et al. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 1996;16:3459–66
   PubMed Web of Science ®Google Scholar
• He J, Li D, Xiong K, et al. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: organoselenium compounds for cancer therapy. Bioorg Med Chem 2012;20:3816–27
   PubMed Web of Science ®Google Scholar
• Fang J, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 2005;280:25284–90
   PubMed Web of Science ®Google Scholar
• Grogan TM, Fenoglio-Prieser C, Zeheb R, et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Human Pathol 2000;31:475–81
   PubMed Web of Science ®Google Scholar
• Smart DK, Ortiz KL, Mattson D, et al. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res 2004;64:6716–24
   PubMed Web of Science ®Google Scholar
• Yoo MH, Xu XM, Carlson BA, et al. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 2006;281:13005–8
   PubMed Web of Science ®Google Scholar
• Yoo MH, Xu XM, Carlson BA, et al. Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS One 2007;2:e1112
   Google Scholar
• Chen W, Seefeldt T, Young A, et al. Design, synthesis, and biological evaluation of N-acetyl-S-(p-chlorophenylcarbamoyl)cysteine and its analogs as a novel class of anticancer agents. Bioorg Med Chem 2011;19:287–94
   PubMed Web of Science ®Google Scholar
• Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 2006;281:10691–7
   PubMed Web of Science ®Google Scholar
• Mura P, Camalli M, Bindoli A, et al. Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound. J Med Chem 2007;50:5871–4
   PubMed Web of Science ®Google Scholar
• Casini A, Gabbiani C, Sorrentino F, et al. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J Med Chem 2008;51:6773–81
   PubMed Web of Science ®Google Scholar
• Arner ES, Holmgren A. Measurement of thioredoxin and thioredoxin reductase. Current protocols in toxicology/editorial board, Mahin D Maines. 2001; chapter 7:Unit 7 4
   Google Scholar
• Kitz R, Wilson IB. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 1962;237:3245–9
   PubMed Web of Science ®Google Scholar
• Rice KP, Klinkerch EJ, Gerber SA, et al. Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine. Mol Cell Biochem 2012;370:199–207
   PubMed Web of Science ®Google Scholar
• Chew EH, Lu J, Bradshaw TD, Holmgren A. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB J 2008;22:2072–83
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Fujii T, Fujii J, Taniguchi N. Roles of N-terminal active cysteines and C-terminal cysteine-selenocysteine in the catalytic mechanism of mammalian thioredoxin reductase. J Biochem 2001;129:803–12
   PubMed Web of Science ®Google Scholar
• Cai W, Zhang L, Song Y, et al. Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic Biol Med 2012;52:257–65
   PubMed Web of Science ®Google Scholar
• Wessjohann LA, Schneider A, Abbas M, Brandt W. Selenium in chemistry and biochemistry in comparison to sulfur. Biol Chem 2007;388:997–1006
   PubMed Web of Science ®Google Scholar